ClinicalTrials.gg
CompletedNCT04174365Updated Aug 28, 2025Results posted

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder

A Phase 3 interventional study of Brexpiprazole and Placebo in Irritability Associated With Autism Spectrum Disorder (ASD), sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Autistic Disorder · Otsuka Holdings Co., Ltd..

Enrollment
4th of 10
119 · median 105
Started
2019
the only one that year
Phase 3
8 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2019, is one of 8 in phase 3, and was the 10th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

None of the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd. is open now. The open studies under Autistic Disorder, anywhere →

Where they have run

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

The purpose of this study is to find out about the potential benefits and safety of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.

03

Conditions studied

  • Irritability Associated With Autism Spectrum Disorder (ASD)

Keywords

  • Autism
  • Irritability
  • Autism Spectrum Disorder
  • ASD
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Primary , Fifth Edition (DSM-5) diagnosis of ASD
  • Aberrant Behavior checklist - Irritability (ABC-I) subscale score of ≥ 18
  • Clinical Global Impressions - Severity (CGI-S) scale score pertaining to irritability ≥ 4
  • Mental age of ≥ 2 years as determined by Investigator based upon school participation, social history or medical records
  • Ability for parent/caregiver to follow all protocol procedures
  • Able to swallow tablets
  • Able to discontinue all prohibited concomitant medications to meet protocol required washouts prior to and during the trial period

Key Exclusion Criteria:

  • Primary diagnosis of bipolar I disorder, including any DSM-5 current diagnosis of bipolar II disorder, schizophrenia, schizoaffective disorder, major depressive episode, and post-traumatic stress disorder (PTSD). Attention-deficit/hyperactivity disorder (ADHD) maybe exclusionary if it is the primary disorder, or is not stable or adequately treated.
  • current or historical diagnosis of Fragile-X Syndrome or Rett's Disorder
  • history of neuroleptic malignant syndrome
  • a significant risk of committing violent acts, serious self-harm, or suicide
  • epilepsy, a history of seizures, or a history of severe head trauma or stroke, or have a history or current evidence of other unstable medical conditions
  • current hypothyroidism or hyperthyroidism
  • uncontrolled Type I or Type II diabetes
  • uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension
  • Weight \< 15 kg
  • Previous exposure to brexpiprazole
  • Sexually active males or females, who could become pregnant, not agreeing to practice 2 different methods of or remain abstinent during the trial and for 30 days at the end of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Participants received flexible doses of brexpiprazole 0.25 to 3 milligram per day (mg/day), orally, once daily (QD) up to Week 8. For participants with body weight \< 50 kilograms (kg) the dose was titrated up from 0.25 mg/day on Days 1 to 3, followed by 0.5 mg on Days 4 to 7, and to 1 mg on Days 8 to 14. Based on the investigator's judgment the dose was increased to 1.5 mg/day after Day 15. The dose was fixed after Week 6 and administration continued for another 2 weeks until Week 8. For participants with body weight ≥ 50 kg the dose was titrated up from 0.5 mg/day on Days 1 to 3, followed by 1.5 mg on Days 4 to 7, and to 2 mg on Days 8 to 14. Based on the investigator's judgment the dose was increased to 3 mg/day after Day 15. The dose was fixed after Week 6 and administration continued for another 2 weeks until Week 8.

    Drug: Brexpiprazole

  • Placebo comparator
    Placebo

    Participants received brexpiprazole matching placebo orally, QD, in the same way as brexpiprazole up to Week 8.

    Drug: Placebo

Interventions

  • Oral tablet; take once daily

    Also known as: brexpiprazole, OPC-34712 and LuAF41156

  • DrugPlacebo

    Administered orally daily for up to Week 8.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Week 8 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score

    The ABC is a parent-reported rating scale designed to assess treatment effects on problem behavior in participants with intellectual disabilities. The ABC scale has 58 items, which divide into 5 subscales as follows: (1) Irritability, Agitation; (2) Lethargy, Social Withdrawal; (3) Stereotypic Behavior; (4) Hyperactivity, Noncompliance; and (5) Inappropriate Speech. Each of the 58 ABC items is rated on a 4-point scale (0=not at all a problem; 1=the behavior is a problem, but slight in degree;2=the problem is moderately serious; 3=the problem is severe in degree). ABC-I measures emotional and behavioral symptoms of ASD, including aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. ABC-I total score is the sum of the ratings over 15 ABC items. Individual scores were summed, thus the ABC-I total score ranges from 0 to 45. Higher scores represent the worst condition. A negative change from baseline indicates improvement.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Mean Change From Baseline to Week 8 in Clinical Global Impression - Severity (CGI-S) Score

    The CGI-S scale is a clinician-rated assessment that evaluates the severity of a participant's condition with a focus on symptoms of irritability on a 7-point scale. The investigator (or rater) answered the following question: "Considering your total clinical experience with this particular population, how ill was the participant at this time with regard to symptoms of irritability?" Response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. Higher scores indicate more severe illness. A negative change from baseline indicates improvement.

    Time frame: Baseline to Week 8

07

Results

Posted Aug 28, 2025

Participant flow

Participants took part in the study at 40 sites in the United States from 30 October 2019 to 9 September 2022.

Participant flow — Overall Study
MilestoneBrexpiprazolePlacebo
Started6059
Randomized sample6059
Safety sample5857
Efficacy sample5856
Completed5252
Not completed87
Withdrew: Lost to follow-up12
Withdrew: Adverse event21
Withdrew: Subject withdrew consent to participate10
Withdrew: Subject was withdrawn from participation by parent/guardian21
Withdrew: Protocol deviation10
Withdrew: Lack of efficacy02
Withdrew: Disease relapse10
Withdrew: Reason not specified01

Outcome measures

PrimaryMean Change From Baseline to Week 8 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score

The ABC is a parent-reported rating scale designed to assess treatment effects on problem behavior in participants with intellectual disabilities. The ABC scale has 58 items, which divide into 5 subscales as follows: (1) Irritability, Agitation; (2) Lethargy, Social Withdrawal; (3) Stereotypic Behavior; (4) Hyperactivity, Noncompliance; and (5) Inappropriate Speech. Each of the 58 ABC items is rated on a 4-point scale (0=not at all a problem; 1=the behavior is a problem, but slight in degree;2=the problem is moderately serious; 3=the problem is severe in degree). ABC-I measures emotional and behavioral symptoms of ASD, including aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. ABC-I total score is the sum of the ratings over 15 ABC items. Individual scores were summed, thus the ABC-I total score ranges from 0 to 45. Higher scores represent the worst condition. A negative change from baseline indicates improvement.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline to Week 8 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score
score on a scaleBrexpiprazolePlacebo
Mean Change From Baseline to Week 8 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score-10.1 ± 1.28-8.87 ± 1.25
Statistical analysis
  • Brexpiprazole vs Placebo · Mixed model repeated measures(MMRM) · p = 0.4597 · Least squares (ls) mean difference: -1.22 · 95% CI -4.49 to 2.05MMRM method with model terms: treatment, trial site, baseline body weight stratum, visit, treatment-by-visit and baseline-by-visit interaction. Significance test was based on least-square means using a two-sided 0.05 level.
SecondaryMean Change From Baseline to Week 8 in Clinical Global Impression - Severity (CGI-S) Score

The CGI-S scale is a clinician-rated assessment that evaluates the severity of a participant's condition with a focus on symptoms of irritability on a 7-point scale. The investigator (or rater) answered the following question: "Considering your total clinical experience with this particular population, how ill was the participant at this time with regard to symptoms of irritability?" Response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. Higher scores indicate more severe illness. A negative change from baseline indicates improvement.

Time frame:
Baseline to Week 8
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline to Week 8 in Clinical Global Impression - Severity (CGI-S) Score
score on a scaleBrexpiprazolePlacebo
Mean Change From Baseline to Week 8 in Clinical Global Impression - Severity (CGI-S) Score-1.16 ± 0.15-1.09 ± 0.15
Statistical analysis
  • Brexpiprazole vs Placebo · MMRM · p = 0.7315 · Ls mean difference: -0.07 · 95% CI -0.46 to 0.32MMRM method with model terms: treatment, trial site, baseline body weight stratum, visit, treatment-by-visit and baseline-by-visit interaction. Significance test was based on least-square means using a two-sided 0.05 level.

Adverse events

Collected over From first dose through 21 days after last dose of study drug (up to Week 11). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole0/58 (0%)0/58 (0%)13/58 (22.4%)
Placebo0/57 (0%)0/57 (0%)5/57 (8.8%)
Most frequent other events
Most frequent other events
EventBrexpiprazolePlacebo
SomnolenceNervous system disorders7/583/57
HeadacheNervous system disorders6/581/57
VomitingGastrointestinal disorders3/581/57

Baseline characteristics

Randomized sample included all participants who were randomized into the trial.

Age, Continuous
Age, Continuous(years)BrexpiprazolePlaceboTotal
Mean9.8 ± 2.910.0 ± 3.29.9 ± 3.0
Sex: Female, Male
Sex: Female, Male(Participants)BrexpiprazolePlaceboTotal
Female6915
Male5450104
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BrexpiprazolePlaceboTotal
Hispanic or Latino8715
Not Hispanic or Latino5252104
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BrexpiprazolePlaceboTotal
Race — White494594
Race — Black or African American31013
Race — American Indian or Alaska Native000
Race — Asian235
Race — Native Hawaiian or Other Pacific Islander101
Race — Other516
Region of Enrollment
Region of Enrollment(participants)BrexpiprazolePlaceboTotal
United States6059119
Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score
Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score(score on a scale)BrexpiprazolePlaceboTotal
Mean29.7 ± 8.028.6 ± 7.629.1 ± 7.8
Clinical Global Impression - Severity (CGI-S) Score
Clinical Global Impression - Severity (CGI-S) Score(score on a scale)BrexpiprazolePlaceboTotal
Mean4.9 ± 0.74.7 ± 0.54.8 ± 0.7
08

Study locations

1 site
  • For additional information regarding sites
    Princeton, New Jersey 08540, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Aug 2022, 33 months.

Results were first posted in Aug 2025, 3 years after primary completion. A results delay was requested in Aug 2023.

Of 15 phase 3 interventional studies under Autistic Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 33 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2019
First posted
Nov 22, 2019
StartActual
Oct 30, 2019
Primary completionActual
Aug 8, 2022
CompletionActual
Sep 9, 2022
Results delay requested
Aug 8, 2023
Results first posted
Aug 28, 2025
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04174365
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Nov 22, 2019
Start date
Oct 30, 2019
Primary completion
Aug 8, 2022
Completion
Sep 9, 2022
Results posted
Aug 28, 2025
Last update
Aug 28, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion